January 10, 2018
GenSight Biologics receives MHRA approval to initiate Phase I/II PIONEER clinical trial of GS030 gene therapy in Retinitis Pigmentosa
Media
January 09, 2018
Pulmonx Submits Premarket Approval (PMA) Application to U.S. FDA for Zephyr Endobronchial Valve as Treatment for Emphysema
January 09, 2018
BioClin Therapeutics Appoints Graeme Currie, Ph.D., as Chief Operating Officer and Esteban (Steve) Abella, M.D., as Chief Medical Officer
January 08, 2018
Targovax announces the appointment of Michael Bogenstaetter as Chief Business Officer
January 06, 2018
Nexstim enrols last patient in supplementary Phase III E-FIT trial
January 04, 2018
Targovax announces that ONCOS-102 generates immune activation in checkpoint inhibitor refractory melanoma patients
January 03, 2018
Altimmune Elects Mitchel Sayare, Ph.D. as Chairman of its Board of Directors
December 21, 2017
Altimmune Announces Positive Initial Data from Its HepTcell Phase 1 Study
December 18, 2017
Targovax announces that TG02 has passed the initial safety review in the first-in-man clinical trial in colorectal cancer
December 14, 2017
WTX101 granted Fast Track designation by the U.S. FDA for the treatment of Wilson Disease